Your browser is no longer supported. Please, upgrade your browser.
Settings
NK NantKwest, Inc. daily Stock Chart
NK [NASD]
NantKwest, Inc.
Index- P/E- EPS (ttm)-0.67 Insider Own25.50% Shs Outstand98.47M Perf Week10.28%
Market Cap1.46B Forward P/E- EPS next Y-0.80 Insider Trans13.73% Shs Float33.78M Perf Month96.51%
Income-66.30M PEG- EPS next Q-0.19 Inst Own5.80% Short Float16.03% Perf Quarter298.82%
Sales0.06M P/S24780.56 EPS this Y42.60% Inst Trans0.35% Short Ratio2.20 Perf Half Y98.82%
Book/sh1.04 P/B13.00 EPS next Y-25.00% ROA-43.80% Target Price10.75 Perf Year1107.14%
Cash/sh0.37 P/C36.28 EPS next 5Y-1.70% ROE-51.90% 52W Range1.04 - 15.34 Perf YTD256.73%
Dividend- P/FCF- EPS past 5Y-54.10% ROI- 52W High-11.85% Beta3.14
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin- 52W Low1200.00% ATR1.41
Employees153 Current Ratio3.10 Sales Q/Q320.00% Oper. Margin- RSI (14)64.81 Volatility11.98% 14.58%
OptionableYes Debt/Eq0.00 EPS Q/Q15.20% Profit Margin- Rel Volume0.89 Prev Close13.21
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.46M Price13.52
Recom2.50 SMA2020.59% SMA5073.07% SMA200206.40% Volume2,257,967 Change2.35%
Jul-08-20Initiated Piper Sandler Overweight $18
May-31-19Downgrade Citigroup Neutral → Sell
Nov-30-18Upgrade Citigroup Sell → Neutral
Oct-17-18Downgrade Citigroup Neutral → Sell
Aug-09-18Upgrade Citigroup Sell → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Mar-17-17Reiterated FBR & Co. Outperform $22 → $9
Jan-24-17Downgrade Jefferies Buy → Hold
Jun-02-16Initiated Raymond James Mkt Perform
Apr-04-16Reiterated Canaccord Genuity Buy $20 → $18
Mar-31-16Reiterated FBR Capital Outperform $30 → $29
Dec-22-15Initiated Canaccord Genuity Buy $20
Oct-28-15Initiated FBR Capital Outperform $30
Aug-24-15Initiated Piper Jaffray Overweight $38
Aug-24-15Initiated MLV & Co Buy $35
Aug-24-15Initiated Jefferies Buy $33
Aug-24-15Initiated Citigroup Buy $45
Jul-06-20 10:48AM  
Jul-02-20 10:24AM  
Jun-29-20 04:05PM  
02:06PM  
Jun-25-20 01:01AM  
Jun-24-20 04:15PM  
Jun-10-20 09:00AM  
May-31-20 09:13PM  
May-27-20 01:56PM  
12:00PM  
May-26-20 09:30AM  
May-19-20 08:00AM  
May-18-20 08:30AM  
May-15-20 07:49AM  
May-14-20 04:25PM  
Apr-29-20 04:15PM  
Apr-14-20 04:55PM  
10:55AM  
08:30AM  
Mar-19-20 08:00AM  
Jan-17-20 08:42AM  
Jan-16-20 08:00AM  
Jan-14-20 08:00AM  
Jan-13-20 05:22PM  
Jan-06-20 11:50AM  
Dec-20-19 02:55PM  
Dec-16-19 07:00AM  
Dec-03-19 07:59AM  
Dec-02-19 04:05PM  
Nov-27-19 08:00AM  
Nov-07-19 04:15PM  
01:14PM  
Oct-02-19 10:40AM  
Aug-27-19 10:21AM  
Jul-11-19 06:58AM  
Jun-24-19 08:00AM  
Jun-06-19 04:10PM  
Jun-04-19 08:00AM  
07:45AM  
Jun-03-19 02:50PM  
08:00AM  
May-31-19 08:00AM  
May-23-19 10:13AM  
May-01-19 08:00AM  
Apr-01-19 08:00AM  
05:42AM  
Mar-25-19 08:00AM  
Mar-18-19 05:00AM  
Mar-04-19 08:00AM  
Feb-25-19 02:13PM  
Jan-10-19 08:50AM  
Jan-09-19 08:00AM  
Jan-07-19 03:36PM  
Jan-05-19 08:00AM  
Dec-25-18 10:03AM  
Dec-18-18 10:30AM  
Dec-03-18 11:00AM  
Nov-08-18 12:56PM  
10:20AM  
Nov-07-18 05:28PM  
Nov-05-18 11:23PM  
Oct-23-18 08:00AM  
06:05AM  
Oct-02-18 12:02PM  
Sep-18-18 01:52PM  
Aug-29-18 08:30AM  
Aug-10-18 03:08PM  
Jul-02-18 08:10AM  
Jun-19-18 05:00AM  
Jun-11-18 07:08AM  
07:00AM  
Jun-05-18 01:29PM  
Apr-23-18 03:18PM  
Mar-13-18 07:29PM  
02:49PM  
Feb-13-18 08:00AM  
Feb-06-18 08:25AM  
Jan-30-18 09:06AM  
07:20AM  
Jan-24-18 02:05PM  
Jan-23-18 06:44PM  
Jan-05-18 06:03PM  
03:44AM  
Dec-28-17 12:30PM  
Dec-27-17 08:35AM  
Dec-12-17 09:45AM  
Dec-04-17 08:00AM  
Nov-21-17 07:59AM  
Oct-24-17 04:51PM  
Oct-11-17 11:52AM  
Oct-04-17 09:30AM  
Sep-26-17 10:59AM  
Sep-22-17 04:39PM  
Sep-21-17 08:01AM  
Aug-31-17 07:38PM  
Aug-24-17 10:11AM  
Aug-15-17 06:18PM  
Aug-09-17 11:50AM  
Aug-07-17 12:59PM  
Aug-02-17 09:12AM  
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Simon Barry J.See remarksJul 08Option Exercise1.7639,95070,1283,210,490Jul 10 05:00 PM
Simon Barry J.See remarksJul 08Sale13.1439,950524,7593,170,540Jul 10 05:00 PM
Simon Barry J.See remarksJun 30Option Exercise1.769163,170,549Jul 02 06:32 PM
Simon Barry J.See remarksJun 30Sale13.0091173,170,540Jul 02 06:32 PM
SOON-SHIONG PATRICKChairman and CEOJun 29Buy12.123,710,00044,965,20023,750,750Jun 29 07:36 PM
Simon Barry J.See remarksJun 23Option Exercise1.7629,60951,9763,200,149Jun 23 09:45 PM
Simon Barry J.See remarksJun 23Sale13.0129,609385,1333,170,540Jun 23 09:45 PM
Simon Barry J.See remarksJun 22Option Exercise1.76136,729240,0143,327,235Jun 23 09:45 PM
Simon Barry J.See remarksJun 22Sale10.24156,6951,604,1803,170,540Jun 23 09:45 PM
Simon Barry J.See remarksJun 19Option Exercise1.769,33716,3903,204,243Jun 23 09:45 PM
Simon Barry J.See remarksJun 19Sale9.0013,737123,6373,190,506Jun 23 09:45 PM
Simon Barry J.See remarksMay 27Sale7.5675,000567,3383,194,906May 29 04:27 PM
Simon Barry J.See remarksMay 21Sale5.5236,932203,6983,269,906May 22 05:37 PM
Simon Barry J.See remarksMay 11Sale5.5028,068154,5093,306,838May 13 08:04 PM
Nelson SonjaChief Financial OfficerMar 23Option Exercise0.0015,000036,542Mar 24 05:47 PM
Thomas John CDirectorDec 16Sale3.1410,00031,400330,069Dec 16 07:40 PM
Thomas John CDirectorDec 13Sale2.7320,00054,600340,069Dec 16 07:40 PM
Thomas John CDirectorDec 12Sale1.9910,00019,918360,069Dec 12 06:29 PM
Thomas John CDirectorSep 09Sale1.2413,95617,305370,069Sep 09 04:42 PM
Thomas John CDirectorSep 06Sale1.247,0808,779384,025Sep 09 04:42 PM
Thomas John CDirectorSep 05Sale1.252,9643,705391,105Sep 09 04:42 PM
Nelson SonjaChief Financial OfficerAug 02Option Exercise0.0010,000025,000Aug 05 05:46 PM